Vardenafil (Levitra/Staxyn) and Sildenafil Interaction

Why Vardenafil and Sildenafil Must Not Be Combined

Taking two PDE5 inhibitors at the same time produces additive vasodilation that the cardiovascular system cannot safely compensate for. Both vardenafil and sildenafil block phosphodiesterase type 5 in corpus cavernosum and systemic vascular smooth muscle, raising cyclic GMP levels and relaxing arterial walls. A single 100 mg dose of sildenafil lowers systolic blood pressure by a mean of 8.4 mmHg and diastolic by 5.5 mmHg in healthy volunteers, according to the FDA-approved prescribing information [1]. Vardenafil 20 mg produces comparable reductions of approximately 7/8 mmHg per the vardenafil label [2].

Stacking those effects risks symptomatic hypotension. Patients may experience dizziness, visual disturbance, presyncope, or frank syncope. The risk intensifies if the patient also takes an alpha-blocker, antihypertensive, or consumes alcohol. No published randomized trial has evaluated dual PDE5 inhibitor therapy for erectile dysfunction, because the theoretical risk-benefit ratio offers no clinical rationale for the combination.

Pharmacodynamic Mechanism in Detail

The interaction is pharmacodynamic, not pharmacokinetic. Both drugs compete for the same molecular target. PDE5 hydrolyzes cyclic guanosine monophosphate (cGMP) in smooth muscle cells. When two inhibitors occupy the enzyme simultaneously, cGMP accumulates beyond the level either drug produces alone.

A 2005 comparative pharmacology review published in the British Journal of Clinical Pharmacology confirmed that vardenafil has roughly 10-fold higher in vitro potency for PDE5 than sildenafil (IC50 0.7 nM vs. 6.6 nM), which is why its clinical dose is lower (5 to 20 mg vs. 25 to 100 mg) [3]. Combining a low-dose vardenafil with sildenafil does not produce a "gentler" effect. It produces unpredictable PDE5 saturation.

The vascular beds most affected include the pulmonary, coronary, and peripheral arterial systems. A 2002 hemodynamic study showed that sildenafil reduced pulmonary vascular resistance by 15 to 20% in patients with pulmonary hypertension (Ghofrani et al., Annals of Internal Medicine) [4]. Adding a second PDE5 inhibitor to that baseline vasodilation creates an unsafe hemodynamic profile. This matters because many men with ED carry comorbid cardiovascular disease.

Pharmacokinetic Overlap and CYP3A4 Considerations

Both vardenafil and sildenafil are metabolized primarily by cytochrome P450 3A4 and, to a lesser extent, CYP2C9 [1][2]. They do not strongly inhibit each other's metabolism at therapeutic concentrations, so the interaction is not driven by plasma level changes. The clinical danger comes from the shared pharmacodynamic endpoint, not from one drug raising the blood concentration of the other.

Any CYP3A4 inhibitor taken alongside either drug (ketoconazole, ritonavir, erythromycin, grapefruit juice) will raise plasma levels of whichever PDE5 inhibitor is present. If a patient mistakenly took both agents while also using a moderate CYP3A4 inhibitor, the result would be elevated concentrations of two drugs that both lower blood pressure. The FDA label for vardenafil specifically contraindicates the 10 mg and 20 mg doses with potent CYP3A4 inhibitors, limiting the dose to 2.5 mg every 72 hours in that scenario [2].

How Drug Interaction Databases Classify This Combination

Major drug interaction databases consistently rate the vardenafil-sildenafil combination as a high-severity interaction. Lexicomp classifies PDE5 inhibitor-PDE5 inhibitor pairs as "X: Avoid Combination." Micromedex rates the interaction as "contraindicated." The Clinical Pharmacology database assigns it a "major" severity rating.

These classifications are based on the pharmacological principle that two drugs sharing an identical mechanism of action will produce additive or supra-additive effects on the target tissue. No dose adjustment makes the combination acceptable. The recommendation across all references is simple: do not use concurrently.

"Patients should be counseled that PDE5 inhibitors are not interchangeable on a dose-for-dose basis and must never be taken simultaneously," states the American Urological Association (AUA) guideline on erectile dysfunction [5]. The correct approach when switching from one PDE5 inhibitor to another is sequential use with an appropriate washout period.

Washout Period When Switching Between Agents

The minimum washout before switching from vardenafil to sildenafil (or vice versa) should be at least 24 hours, which represents approximately five half-lives of either drug. Vardenafil's terminal half-life is 4 to 5 hours for the film-coated tablet and 4 to 6 hours for the orally disintegrating tablet (Staxyn) [2]. Sildenafil's half-life is 3 to 5 hours [1].

After five half-lives (roughly 20 to 25 hours), residual plasma concentrations fall below 5% of peak, making clinically meaningful additive vasodilation unlikely. A 24-hour gap provides a reasonable safety margin for most patients.

Patients with hepatic impairment or those taking CYP3A4 inhibitors need longer washout periods. The vardenafil label states that clearance is reduced by 130% in moderate hepatic impairment (Child-Pugh B), extending the effective half-life considerably [2]. For these patients, a 48- to 72-hour washout is more appropriate before introducing sildenafil.

Blood Pressure Risks in Patients Taking Antihypertensives

Men with erectile dysfunction frequently take antihypertensive medications. A 2004 analysis in the Journal of the American College of Cardiology found that 68% of men with ED had at least one cardiovascular risk factor, and 38% were on antihypertensive therapy (Thompson et al., JAMA) [6]. The hemodynamic effects of even a single PDE5 inhibitor add to the blood-pressure-lowering action of antihypertensives.

Sildenafil with amlodipine produces an additional mean supine systolic drop of 8 mmHg and diastolic drop of 7 mmHg beyond amlodipine alone [1]. Vardenafil combined with tamsulosin 0.4 mg increased standing systolic blood pressure decreases, with outlier responses (systolic drops exceeding 30 mmHg) occurring in a proportion of subjects [2].

Adding two PDE5 inhibitors on top of background antihypertensive therapy could produce drops exceeding 30 to 40 mmHg systolic. This level of hypotension risks end-organ hypoperfusion, particularly in elderly patients or those with fixed cardiac output from aortic stenosis or hypertrophic cardiomyopathy. A brief drop this severe can trigger falls, myocardial ischemia, or stroke.

Nitrate Interaction: A Compounding Danger

Both vardenafil and sildenafil are absolutely contraindicated with organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate). Nitrates work through the same NO-cGMP pathway, and combining a nitrate with even one PDE5 inhibitor can cause profound, potentially fatal hypotension.

A landmark 2003 study by Webb et al. demonstrated that sildenafil potentiated the hypotensive effect of sublingual glyceryl trinitrate by 25 to 50 mmHg in healthy volunteers [7]. The ACC/AHA guidelines state that nitrates must not be administered within 24 hours of sildenafil or 48 hours of vardenafil (vardenafil's longer interaction window stems from its higher PDE5 affinity) [8].

A patient who mistakenly took both vardenafil and sildenafil and then required nitroglycerin for chest pain would face a triple pharmacodynamic interaction. Emergency physicians must be told exactly what was taken and when, because nitrate administration in this context is contraindicated.

Clinical Scenarios Where Patients Might Combine These Drugs

Prescribers should understand why patients sometimes attempt this combination. Three scenarios account for most cases:

Switching without waiting. A man unsatisfied with sildenafil's response might take vardenafil the same evening. Without explicit washout counseling, this is the most common accidental overlap.

Performance anxiety dosing. Some patients take a second PDE5 inhibitor as "backup" when the first does not produce an erection within their expected timeframe. The sildenafil label states onset occurs within 30 to 60 minutes, but individual variation extends to 120 minutes in some men [1].

Obtained from different sources. A patient may have a prescription for one drug and purchase the other from an online pharmacy or international source without disclosing it to their prescriber.

In each case, the clinical response should include direct counseling: one PDE5 inhibitor at a time, prescribed dose only, minimum 24-hour gap before switching. Documentation of the counseling conversation protects both patient and clinician.

What To Do If Both Drugs Were Taken

If a patient reports taking both vardenafil and sildenafil within the same dosing window, management is supportive and monitoring-focused. Check orthostatic vital signs immediately. Symptomatic hypotension (systolic below 90 mmHg or a drop exceeding 20 mmHg on standing) warrants supine positioning with legs elevated and IV normal saline if needed.

Do not administer nitrates. Do not administer alpha-agonists (phenylephrine, midodrine) unless hypotension is refractory, because the interaction is self-limited by drug clearance. Both drugs will fall below clinically active levels within 12 to 16 hours in patients with normal hepatic function.

Monitor for priapism. Additive PDE5 inhibition increases the theoretical risk of prolonged erection lasting more than 4 hours. If priapism occurs, standard management with intracavernosal phenylephrine injection applies per AUA priapism guidelines [9].

"The management of PDE5 inhibitor-related hypotension is supportive. Vasopressors are rarely required, and the episode is typically self-limited," notes the Endocrine Society's clinical practice guideline on testosterone therapy [10], which addresses PDE5 inhibitor use in the context of hypogonadal men with ED.

Choosing Between Vardenafil and Sildenafil

Patients who have tried one agent and want to switch to the other should do so sequentially. A 2011 meta-analysis of 82 randomized controlled trials (N = 47,626) published in European Urology found no statistically significant difference in efficacy between PDE5 inhibitors as a class for erectile dysfunction, though individual response varies [11].

Vardenafil may suit patients who want a slightly longer duration (the Staxyn ODT formulation has a Tmax of 1.0 to 1.5 hours, similar to sildenafil, but some patients report subjectively longer effect windows). Sildenafil has the longest track record and broadest generic availability. The choice between them is clinical, not additive.